相关实验视频
Updated: Jan 16, 2026

08:36
Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
1.5K
慢性光皮炎的三个病例成功地用upadacitinib治疗
Hissa Al-Marri1,2, Wadha Al-Shafi1,2, Mohammed Al-Abdula1,2
1Department of Dermatology and Venereology, Hamad Medical Corporation, Doha, Qatar.
Skin health and disease
|October 2, 2025
概括
乌帕达西替尼 (Upadacitinib) 是一种Janus激酶1抑制剂,有效治疗了三名患者的慢性光皮炎. 这种疗法提供了显著的,持久的症状缓解与这些免疫介导的皮肤病的良好的安全性.
科学领域:
- 皮肤病学 皮肤病学
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 光皮肤病是紫外线辐射引发的皮肤疾病,涉及免疫介导反应.
- 烧伤,和可见的病变等症状显著损害了患者的生活质量.
- 目前用于光皮病的治疗方法具有可变的疗效和潜在的不良事件.
研究的目的:
- 评估乌帕达西提尼布在治疗慢性光皮炎中的疗效和安全性.
- 评估upadacitinib作为对复发性光皮肤病例的单一疗法.
主要方法:
- 追溯三名慢性光皮炎患者的病例系列.
- 作为单疗法使用选择性Janus激酶1抑制剂upadacitinib的治疗.
- 根据迹象,症状和安全概况评估临床结果.
主要成果:
- 这三名患者在光皮炎的症状和体征中都经历了快速,显著和持续的改善.
- 在这个队列中,upadacitinib表现出了有利的安全性和耐受性概况.
- 治疗有效地管理了光皮病的特征,即免疫介导的延迟过敏反应.
结论:
- 在Upadacitinib单一治疗中,Upadacitinib为慢性光皮炎提供了一个有前途的治疗选择.
- 这种JAK1抑制剂提供了一个潜在的有效和安全的替代方案,用于管理严重的光皮肤病.
- 需要进一步的研究来证实这些发现在更大的患者群体中.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
493
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
493
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
492
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
492

